2024-519010-31-00Not yet recruitingPhase 1
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Oct 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 21 May 2025
- Start date
- 2 Sept 2025
- Lead sponsor
- Fondazione Melanoma Onlus
- Diseases
- Melanoma
- EU CT number
- 2024-519010-31-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 80
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (8)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l | Meldola | Italy | Not yet recruiting |
| Istituto Europeo di Oncologia s.r.l | Milan | Italy | Not yet recruiting |
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | Not yet recruiting |
| IRCCS Istituto Nazionale Tumori Fondazione Pascale | Naples | Italy | Not yet recruiting |
| Azienda Ospedaliera Universitaria - Universita degli Studi della Campania Luigi Vanvitelli | Naples | Italy | Not yet recruiting |
| Istituto Oncologico Veneto | Padova | Italy | Not yet recruiting |
| Hospital Santa Maria Della Misericordia | Perugia | Italy | Not yet recruiting |
| I.F.O. Istituti Fisioterapici Ospitalieri | Rome | Italy | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.